Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $405.4M
- Enterprise value
- $405.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $13.24
- 52-wk low
- $1.50
- Beta
- —
- Shares out
- 82.6M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business Overview We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. Oncolytic immunotherapy exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. Our product candidates incorporate multiple mechanisms into a practical…
AI summary unavailable — showing raw filing excerpt
Generated from REPL's filing dated 2025-05-22
Key risks
Item 1A. Risk factors Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including our audited consolidated financial statements and related notes and “Management’s discussion and analysis of results of operations and financial condition.” If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. The risks and uncertainties…
AI summary unavailable — showing raw filing excerpt
Generated from REPL's filing dated 2025-05-22
Profitability
Return on equity
-59.5%
3.2%Return on assets
-44.9%
1.4%Leverage
Debt / equity
0.33×
7.8%Long-term debt / equity
0.11×
6.8%Debt / assets
24.6%
5.9%Earnings tracker
Not enough quarterly history for REPL yet to draw an earnings tracker.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on REPL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$833.0K
Net activity
−$833.0K
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns REPL
Institutional value
$140.4M
Total shares held
18.8M
Distinct holders
81
-84 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.2M | $47.7M | +169.6K (+2.8%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.8M | $21.1M | — | New |
| 3 | Erste Asset Management GmbH | 2.1M | $15.3M | +0 (+0.0%) | No change |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $8.7M | +20.7K (+1.9%) | Added |
| 5 | JPMORGAN CHASE & CO | 790.0K | $5.7M | -135.2K (-14.6%) | Trimmed |
| 6 | Jefferies Financial Group Inc. | 714.2K | $5.5M | -1 (-0.0%) | Trimmed |
| 7 | UBS Group AG | 581.2K | $4.4M | -23.1K (-3.8%) | Trimmed |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 552.6K | $4.2M | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 475.1K | $3.6M | — | New |
| 10 | JANE STREET GROUP, LLC | 428.1K | $3.3M | -156.2K (-26.7%) | Trimmed |
| 11 | Candriam S.C.A. | 394.0K | $3.0M | — | New |
| 12 | TD ASSET MANAGEMENT INC | 242.6K | $1.9M | -23.9K (-9.0%) | Trimmed |
| 13 | Bank of New York Mellon Corp | 204.8K | $1.6M | -4.4K (-2.1%) | Trimmed |
| 14 | NAN FUNG TRINITY (HK) LTD | 196.3K | $1.5M | -379.2K (-65.9%) | Trimmed |
| 15 | Invesco Ltd. | 190.9K | $1.5M | -422.1K (-68.9%) | Trimmed |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 158.4K | $1.2M | -302.3K (-65.6%) | Trimmed |
| 17 | Walleye Capital LLC | 143.2K | $1.1M | — | New |
| 18 | Hudson Bay Capital Management LP | 131.0K | $1.0M | -22.7K (-14.7%) | Trimmed |
| 19 | RHUMBLINE ADVISERS | 87.7K | $671.2K | -1.6K (-1.8%) | Trimmed |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 86.9K | $664.9K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once REPL's latest filing finishes processing.